⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Polycystic Ovary Syndrome (PCOS) affects an estimated 1 in 5 Indian women of reproductive age — one of the highest rates globally. The condition is deeply intertwined with insulin resistance, weight gain, and hormonal imbalance, making GLP-1 receptor agonists (like semaglutide and liraglutide) an area of growing research interest for PCOS management.
This guide explains what the research currently shows, what Indian women should realistically expect, and how to have an informed conversation with your gynaecologist or endocrinologist.
Important: Consult your healthcare provider before starting any medication. GLP-1 medications are not currently approved in India specifically for PCOS — they are approved for Type 2 Diabetes and, in some cases, obesity management.
PCOS is a hormonal disorder characterised by:
In India, studies including an ICMR consensus statement show that 50–70% of women with PCOS have insulin resistance, even those who are not overweight (a pattern known as lean PCOS, which is particularly common in South Asian women).
Insulin resistance causes the pancreas to overproduce insulin, which in turn stimulates the ovaries to produce excess testosterone — a vicious hormonal cycle that worsens PCOS symptoms. Breaking this cycle is central to PCOS management.
GLP-1 receptor agonists work via several mechanisms relevant to PCOS:
| Mechanism | Potential Benefit for PCOS |
|---|---|
| Improves insulin sensitivity | Reduces ovarian androgen (testosterone) production |
| Promotes significant weight loss | Further reduces insulin resistance |
| Slows gastric emptying | Reduces post-meal blood sugar spikes |
| Reduces systemic inflammation | May improve ovarian function |
| Reduces appetite | Supports sustainable calorie reduction |
A 2023 systematic review in Frontiers in Endocrinology analysed multiple trials of semaglutide and liraglutide in women with PCOS. Key findings included:
A 2022 clinical study published in the Journal of Clinical Endocrinology & Metabolism found that liraglutide combined with lifestyle changes produced significantly better outcomes for menstrual regularity and androgen levels versus lifestyle changes alone in women with PCOS and obesity.
Important caveat: Most trials are small (under 200 participants) and short-term (under 12 months). GLP-1 medications are not yet a standard of care for PCOS — they are an emerging, promising option.
Metformin is currently the most commonly prescribed medication for insulin-resistant PCOS in India. Here is how GLP-1 medications compare:
| Feature | Metformin | GLP-1 Agonists (e.g., Semaglutide) |
|---|---|---|
| Monthly cost | ₹50–₹200 | ₹3,500–₹12,000 |
| Weight loss effect | Modest (1–3 kg) | Significant (5–15% body weight) |
| Menstrual regularity | Moderate evidence | Emerging evidence |
| Androgen reduction | Indirect | Indirect (via insulin reduction) |
| GI side effects | Nausea, diarrhoea | Nausea, vomiting (usually temporary) |
| CDSCO approval for PCOS | Off-label use | Off-label use |
| Route | Oral tablet (daily) | Injection (weekly or daily) |
| Availability in India | Widely available | Available, but limited access |
Bottom line for Indian women: Metformin remains the affordable, accessible, well-studied first-line option for insulin-resistant PCOS in India. GLP-1 medications may be considered by your doctor when:
Unlike Western populations, Indian women frequently present with lean PCOS — normal or even low BMI but significant insulin resistance. GLP-1 medications have less evidence for lean PCOS specifically. Your endocrinologist will need to evaluate your fasting insulin, HOMA-IR, and hormonal profile carefully before recommending GLP-1 therapy.
High-carbohydrate traditional Indian dietary patterns — excess white rice, maida-based breads, sweets during festivals — worsen insulin resistance and PCOS symptoms. GLP-1 medications work best when combined with dietary changes:
If you are trying to conceive or are pregnant, discuss GLP-1 medications carefully with your reproductive endocrinologist:
| Brand | Generic Name | Route | Approx. Cost/Month |
|---|---|---|---|
| Ozempic (Novo Nordisk) | Semaglutide | Weekly subcutaneous injection | ₹10,000–₹12,000 |
| Victoza (Novo Nordisk) | Liraglutide | Daily subcutaneous injection | ₹8,000–₹10,000 |
| Rybelsus (Novo Nordisk) | Oral semaglutide | Daily tablet | ₹6,000–₹8,000 |
| Semaglutide (Biocon) | Semaglutide | Weekly subcutaneous injection | ₹3,500–₹5,000 |
Prices are approximate as of early 2025. Prices as of scraped date may differ — check current prices on our Drugs page.
When visiting your gynaecologist or endocrinologist, you can say:
"I have PCOS with insulin resistance. I've been reading about GLP-1 medications like semaglutide being studied for PCOS. Given my weight and insulin levels, could this be appropriate for me alongside my current treatment?"
Bring these test reports if you have them:
GLP-1 medications are generally not recommended if you:
